Annual Report for the Financial Year Ended March 31, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Chandra Bhagat Pharma Limited submitted its 22nd Annual Report for FY 2024-25 to BSE. The company reported a sharp decline in revenue, with income from operations falling to Rs. 8,671.61 Lacs from Rs. 22,137.19 Lacs in the previous year, a drop of about 61%. Total revenue stood at Rs. 9,220.48 Lacs compared to Rs. 23,270.49 Lacs earlier. Profit before tax (PBT) fell to Rs. 116.54 Lacs from Rs. 226.19 Lacs, and profit after tax (PAT) declined to Rs. 85.78 Lacs from Rs. 153.03 Lacs. The Board has not recommended any dividend, choosing to retain profits for future expansion. The 22nd AGM is scheduled for September 30, 2025, and includes the re-appointment of Mr. Hemant Chandravadan Bhagat as a director.
The steep decline in both revenue and profits is a concern for shareholders and could weigh negatively on the stock. However, the company's decision to skip dividends to plough back profits signals management's focus on future growth, which may be viewed positively by long-term investors.